FDA seeks additional trial on Zalviso drug-device combo from AcelRx

The FDA wants AcelRx Pharmaceuticals to run another clinical trial before it can approve the Zalviso drug-device combination for pain.

(Reuters) — AcelRx Pharmaceuticals (NSDQ:ACRX) said the FDA wants an additional study on its Zalviso drug-device combination, which the safety watchdog already rejected once last year.

AcelRx, Food & Drug Administration (FDA)

News Well, Drug-Device Combinations, Pain Management, Regulatory/Compliance

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1FAAUeo